# PBLD

Source: https://onco.cc/targets/pbld/  
OnCo record `pbld` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PBLD (Phenazine biosynthesis-like domain-containing protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.

## Summary

Functions as a positive regulator of the antiviral immune response by modulating innate immunity and viral replication by enhancing type I interferon (IFN-I) response. PBLD enhances IFN-I signalling via multiple pathways. Promotes IRF3-mediated IFN-I production and apoptosis, thereby inhibiting viral replication.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: phenazine biosynthesis like protein domain containing; Phenazine biosynthesis-like domain-containing protein; MAWBP; MAWDBP; FLJ14767
- Tags: cancer-genes-wave
- Symbol: PBLD
- Class: other
- Biology: Functions as a positive regulator of the antiviral immune response by modulating innate immunity and viral replication by enhancing type I interferon (IFN-I) response. PBLD enhances IFN-I signalling via multiple pathways. Promotes IRF3-mediated IFN-I production and apoptosis, thereby inhibiting viral replication. Up-regulates IFN-I response by activating the NF-kappaB signalling pathway, potentially through inhibition of TRIM21-mediated degradation of phosphorylated IKKbeta, thereby sustaining NF-kappaB activation to counteract viral infection. Additionally, promotes the p53-USP4-MAVS signalling axis by stabilising MAVS through USP4-mediated deubiquitination, thereby enhancing the IFN-I response against RNA virus infection. Acts as a tumour suppressor, regulating development of various cancers. Locus 10q21.3 (HGNC).
- Where found: Hepatocellular carcinoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:23301: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23301
- UniProt P30039: https://www.uniprot.org/uniprotkb/P30039/entry
- NCBI Gene 64081: https://www.ncbi.nlm.nih.gov/gene/64081
- Ensembl ENSG00000108187: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108187

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/pbld.json